Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Vismodegib
Drug ID BADD_D02365
Description Vismodegib inhibits the hedgehog signalling pathway and is indicated for treatment of adult basal cell carcinoma. FDA approved on Jan 30, 2012.
Indications and Usage Vismodegib is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery, and in patients who are not candidates for surgery or radiation.
Marketing Status Prescription
ATC Code L01XJ01
DrugBank ID DB08828
KEGG ID D09992
MeSH ID C538724
PubChem ID 24776445
TTD Drug ID D03EDQ
NDC Product Code 50242-140
Synonyms HhAntag691 | NSC 747691 | NSC747691 | NSC-747691 | R 3616 | R3616 cpd | R-3616 | vismodegib | erivedge | GDC 0449 | GDC0449 | GDC-0449 | RG 3616 | RG3616 | RG-3616
Chemical Information
Molecular Formula C19H14Cl2N2O3S
CAS Registry Number 879085-55-9
SMILES CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Appetite disorder19.09.01.002; 14.03.01.0040.000533%Not Available
Brain neoplasm17.20.01.003; 16.30.01.0030.000139%Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.01.01.003--Not Available
Connective tissue disorder15.06.01.006--Not Available
Feeding disorder19.09.01.003; 14.03.02.0030.000799%Not Available
Embolism24.01.01.0090.000625%
Ischaemic stroke24.04.06.010; 17.08.01.018--Not Available
Malnutrition14.03.02.0040.000533%Not Available
Metastatic neoplasm16.16.01.0070.000208%Not Available
Neoplasm progression16.16.02.005--Not Available
Upper limb fracture15.08.03.018; 12.04.01.0180.000799%Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.025043%
Erectile dysfunction21.03.01.007; 19.08.04.0010.001332%
Ill-defined disorder08.01.03.0490.002931%Not Available
Urinary tract obstruction20.08.01.0040.000533%
Disease progression08.01.03.0380.001807%
Disease recurrence08.01.03.0500.001598%Not Available
Drug intolerance08.06.01.013--Not Available
Neoplasm recurrence16.16.02.0040.000208%Not Available
Investigation13.18.01.004--Not Available
Metastasis16.22.01.0010.000139%Not Available
Renal impairment20.01.03.0100.002664%Not Available
Unevaluable event08.01.03.051--Not Available
Poor quality sleep19.02.05.005; 17.15.04.0020.000533%Not Available
Radiation skin injury23.03.11.007; 12.05.02.0040.000533%
Hypophagia14.03.01.006; 07.01.06.010; 19.09.01.0040.001598%Not Available
Bone marrow failure01.03.03.005--
Treatment failure08.06.01.017--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
The 11th Page    First    Pre   11 12    Next   Last    Total 12 Pages